Show simple item record

dc.contributor.authorPappo, A
dc.contributor.authorPatel, S
dc.contributor.authorCrowley, J
dc.contributor.authorReinke, D
dc.contributor.authorKuenkele, K
dc.contributor.authorChawla, S
dc.contributor.authorToner, G
dc.contributor.authorMaki, R
dc.contributor.authorMeyers, P
dc.contributor.authorChugh, R
dc.contributor.authorGanjoo, K
dc.contributor.authorSchuetze, S
dc.contributor.authorJuergens, H
dc.contributor.authorLeahy, Michael G
dc.contributor.authorGeoerger, B
dc.contributor.authorBenjamin, R
dc.contributor.authorHelman, L
dc.contributor.authorBaker, L
dc.date.accessioned2012-05-02T12:19:26Z
dc.date.available2012-05-02T12:19:26Z
dc.date.issued2011-12-01
dc.identifier.citationR1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. 2011, 29 (34):4541-7 J Clin Oncolen_GB
dc.identifier.issn1527-7755
dc.identifier.pmid22025149
dc.identifier.doi10.1200/JCO.2010.34.0000
dc.identifier.urihttp://hdl.handle.net/10541/221552
dc.description.abstractThe type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a multicenter phase II study of the fully human IGF-1R monoclonal antibody R1507 in patients with recurrent or refractory ESFT.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshBone Neoplasms
dc.subject.meshChild
dc.subject.meshDrug Administration Schedule
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshReceptor, IGF Type 1
dc.subject.meshRecurrence
dc.subject.meshSarcoma, Ewing
dc.subject.meshTreatment Outcome
dc.titleR1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.en
dc.typeArticleen
dc.contributor.departmentSt Jude Children’s Research Hospital, Memphis, TN, USA.en_GB
dc.identifier.journalJournal of Clinical Oncologyen_GB
html.description.abstractThe type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a multicenter phase II study of the fully human IGF-1R monoclonal antibody R1507 in patients with recurrent or refractory ESFT.


This item appears in the following Collection(s)

Show simple item record